V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Neurocrine BioSciences Executive Compensation (FY25)

NBIX · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): May 28, 2026
409 figures on this page: 399 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Total compensation for Kyle Gano, Chief Executive Officer and Director, came to $13,448,935 in fiscal 2025, and for fiscal 2025, the company reported a chief executive pay ratio of 49:1, against median employee compensation of $273,341. For fiscal 2025, shareholders backed the say-on-pay proposal with 93.2% of votes cast including abstentions in favor at the meeting held May 27, 2026. The disclosed peer group includes ACADIA Pharmaceuticals, Inc., Alkermes plc, Alnylam Pharmaceuticals, Inc., argenx SE and BeOne Medicines Ltd., among others. The fiscal 2025 disclosure covers 6 named executive officers.
Chief executive, fiscal 2025
◇
Kyle Gano
Median of the other named officers
$6,311,912
5 officers, excluding the chief executive
Latest say-on-pay support
=
May 27, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Kyle Gano: $8,535,422 → $13,448,935 (57.6% higher)
Say-on-pay support: 91.0% → 93.2% (2.2 points higher)
CEO pay ratio: 35:1 → 49:1 (40.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Neurocrine BioSciences' chief executive and what were they paid?
Total compensation for Kyle Gano, Chief Executive Officer and Director, came to $13,448,935 in fiscal 2025. Gano's total was 57.6% higher than the $8,535,422 reported for fiscal 2024.
What was Neurocrine BioSciences' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 93.2% of votes cast including abstentions in favor at the meeting held May 27, 2026.
Which companies are in Neurocrine BioSciences' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals, Inc., Alkermes plc, Alnylam Pharmaceuticals, Inc., argenx SE and BeOne Medicines Ltd., among others.
What is Neurocrine BioSciences' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 49:1, against median employee compensation of $273,341.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin C. Gorman
Former President and Chief Executive Officer
◇◇◇◇——◇◇
Kyle W. Gano
President and Chief Executive Officer
◇◇◇◇——◇◇
Matthew C. Abernethy
Executive Vice President, Chief Financial Officer
◇◇◇◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin C. Gorman
Former President and Chief Executive Officer
◇◇◇◇——◇◇
Jude Onyia
Executive Vice President, Chief Scientific Officer
◇◇◇◇——◇◇
Matthew C. Abernethy
Executive Vice President, Chief Financial Officer
◇◇◇◇——◇◇
Kyle W. Gano
President and Chief Executive Officer
◇◇◇◇——◇◇
Eiry W. Roberts
Executive Vice President, Chief Medical Officer
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kevin C. Gorman
Former President and Chief Executive Officer
Departed during or after this year
◇◇◇◇——◇◇
Kyle W. Gano
President and Chief Executive Officer
◇◇◇◇——◇◇
Jude Onyia
Executive Vice President, Chief Scientific Officer
◇◇◇◇——◇◇
Eiry W. Roberts
Executive Vice President, Chief Medical Officer
◇◇◇◇——◇◇
Matthew C. Abernethy
Executive Vice President, Chief Financial Officer
◇◇◇◇——◇◇
Eric Benevich
Executive Vice President, Chief Commercial Officer
◇◇◇◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kyle Gano
Chief Executive Officer and Director
◇◇◇◇——◇◇
Sanjay Keswani
Chief Medical Officer
◇◇◇◇——◇◇
Jude Onyia
Chief Scientific Officer
◇◇◇◇——◇◇
Matthew Abernethy
Chief Financial Officer
◇◇◇◇——◇◇
Eiry Roberts
Strategic Advisor
◇◇◇◇——◇◇
Eric Benevich
Chief Commercial Officer
◇◇◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Eiry W. RobertsRSU◇——◇——◇
Eiry W. RobertsOPTION◇——◇—◇◇
Eiry W. RobertsPSU◇◇◇—◇—◇
Eric BenevichOPTION◇——◇—◇◇
Eric BenevichRSU◇——◇——◇
Eric BenevichPSU◇◇◇—◇—◇
Jude OnyiaOPTION◇——◇—◇◇
Jude OnyiaRSU◇——◇——◇
Jude OnyiaPSU◇◇◇—◇—◇
Kyle W. GanoOPTION◇——◇—◇◇
Kyle W. GanoPSU◇◇◇—◇—◇
Kyle W. GanoRSU◇——◇——◇
Matthew C. AbernethyOPTION◇——◇—◇◇
Matthew C. AbernethyRSU◇——◇——◇
Matthew C. AbernethyPSU◇◇◇—◇—◇
Sanjay KeswaniPSU◇◇◇—◇—◇
Sanjay KeswaniPSU◇◇◇—◇—◇
Sanjay KeswaniRSU◇——◇——◇
Sanjay KeswaniOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Eric BenevichRSU◇◇——
Option◇—◇2/13/2034
Option◇—◇1/31/2032
RSU◇◇——
RSU◇◇——
Option◇—◇2/12/2035
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇2/13/2033
Eiry RobertsOption◇—◇12/17/2034
RSU◇◇——
Option◇—◇2/13/2033
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/12/2035
Option◇—◇1/31/2032
RSU◇◇——
Option◇—◇2/13/2034
RSU◇◇——
RSU◇◇——
Kyle GanoOption◇—◇11/1/2034
RSU◇◇——
Option◇—◇2/13/2033
Option◇—◇1/31/2032
RSU◇◇——
Option◇—◇2/13/2034
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇2/12/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Jude OnyiaRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇1/31/2032
RSU◇◇——
Option◇—◇2/12/2035
Option◇—◇2/13/2033
PSU◇◇——
RSU◇◇——
Option◇—◇2/13/2034
Matthew AbernethyOption◇—◇2/12/2035
PSU◇◇——
Option◇—◇1/31/2032
Option◇—◇2/13/2034
RSU◇◇——
Option◇—◇2/13/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Sanjay KeswaniPSU◇◇——
Option◇—◇6/2/2035
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
William H. Rastetter
Board chair
◇◇————◇
Shalini Sharp
◇◇◇———◇
Stephen A. Sherwin
◇◇————◇
Richard F. Pops
◇◇————◇
Christine A. Poon
◇◇————◇
George J. Morrow
◇◇————◇
Leslie V. Norwalk
◇◇◇———◇
Kevin C. Gorman
◇—◇———◇
Gary A. Lyons
◇◇◇———◇
Johanna Mercier
◇◇————◇
Kyle W. Gano served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • ACADIA Pharmaceuticals, Inc. ACAD
  • Alkermes plc ALKS
  • Alnylam Pharmaceuticals, Inc. ALNY
  • argenx SE ARGX
  • BeOne Medicines Ltd. ONC
  • Biogen Inc. BIIB
  • Biomarin Pharmaceutical Inc. BMRN
  • Exelixis, Inc. EXEL
  • Incyte Corporation INCY
  • Ionis Pharmaceuticals, Inc. IONS
  • Jazz Pharmaceuticals plc JAZZ
  • Moderna, Inc. MRNA
  • Organon & Co. OGN
  • Sarepta Therapeutics, Inc. SRPT
  • Ultragenyx Pharmaceutical Inc RARE
  • United Therapeutics Corporation UTHR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 27, 2026=◇◇◇
2024May 21, 2025=◇◇◇
2023May 22, 2024=◇◇◇
2022May 17, 2023=◇◇◇
2021May 18, 2022=◇◇◇
2020May 19, 2021=◇◇◇
2019May 19, 2020=◇◇◇
2018May 22, 2019=◇◇◇
2017May 24, 2018=◇◇◇
2016May 22, 2017=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Neurocrine BioSciences files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Neurocrine BioSciences disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Neurocrine BioSciences sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Neurocrine BioSciences' disclosed peer group is defensible, who names Neurocrine BioSciences back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
409 figures on this page: 399 cited to the filing that reported them, 10 calculated from figures it prints.
399 cited to the filing
10 calculated from the filing

Documents cited

  1. 0000914475-26-000029
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000914475-26-000015
    CEO Pay Ratio · Director Compensation Table · Grants of Plan-Based Awards During 202 · Non-Employee Director Compensation for 2025 · and 2 more sections
  3. 0000914475-25-000120
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000914475-25-000091
    Summary Compensation Table
  5. 0000914475-24-000140
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000914475-24-000106
    Summary Compensation Table
  7. 0001193125-23-149520
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0000914475-23-000032
  9. 0000914475-22-000028
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0000914475-21-000040
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001564590-20-026550
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-19-155346
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-18-178679
    Item 5.07 Submission of Matters to a Vote of Security Holders
  14. 0001193125-17-181670
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Neurocrine BioSciences executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/NBIX (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Neurocrine BioSciences and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Neurocrine BioSciences discloses

The companies named in NBIX's own disclosed peer group.

ACADIA Pharmaceuticals, Inc.Alkermes plcAlnylam Pharmaceuticals, Inc.Biogen Inc.Biomarin Pharmaceutical Inc.Exelixis, Inc.Incyte CorporationIonis Pharmaceuticals, Inc.Jazz Pharmaceuticals plcModerna, Inc.Sarepta Therapeutics, Inc.Ultragenyx Pharmaceutical IncUnited Therapeutics Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy